Obesity & liver diseases

Product Name
Preclinical
Phase 1
Phase 2
Phase 3
Status1
Preclinical
Phase 1
Phase 2
Phase 3
Pemvidutide
(ALT-801)

Obesity

55%
Status2
MOMENTUM trial:  Interim 24-wk weight loss data in Q1 2023
MOMENTUM trial:  Top line 48-wk weight loss data in Q4 2023
Pemvidutide
(ALT-801)

NASH

45%
Status2
24-wk NAFLD readout completed Q4 2022
Initiation of Phase 2b NASH trial mid-year 2023
Preclinical
Phase 1
Phase 2
Phase 3
HepTcell

Chronic HBV

55%
Status2
Top line data readout Q1 2024